Bio Ebit Per Revenue vs Capex To Revenue Analysis

TECH Stock

USD 75.36 0.02 0.03%

Bio Techne financial indicator trend analysis is way more than just evaluating Bio Techne Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Techne Corp is a good investment. Please check the relationship between Bio Techne Ebit Per Revenue and its Capex To Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Ebit Per Revenue vs Capex To Revenue

Ebit Per Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Techne Corp Ebit Per Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Bio Techne's Ebit Per Revenue and Capex To Revenue is -0.01. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Bio Techne Corp, assuming nothing else is changed. The correlation between historical values of Bio Techne's Ebit Per Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Bio Techne Corp are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Ebit Per Revenue i.e., Bio Techne's Ebit Per Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ebit Per Revenue

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Bio Techne's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Techne Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

The Bio Techne's current Selling General Administrative is estimated to increase to about 416.7 M. The Bio Techne's current Tax Provision is estimated to increase to about 24.5 M

	2021	2022	2023	2024 (projected)
Total Revenue	1.1B	1.1B	1.2B	1.2B
Depreciation And Amortization	101.1M	107.2M	111.7M	117.3M

Total Revenue Depreciation And Amortization

Bio Techne fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Intangible Assets	Property Plant And Equipment Gross	Common Stock Total Equity	Short Term Investments
Total Assets		0.9	0.66	0.93	0.98	0.96	0.74	0.98	0.25	0.99	0.29	0.07	0.97	0.93	0.87	0.97	0.9	0.95	0.91	0.87	0.85	0.5	0.9	0.86	0.71	-0.38
Short Long Term Debt Total	0.9		0.46	0.86	0.79	0.76	0.93	0.83	0.06	0.92	0.19	-0.09	0.84	0.76	0.99	0.81	0.75	0.75	0.99	0.65	0.7	0.73	0.96	0.64	0.49	-0.35
Other Current Liab	0.66	0.46		0.81	0.68	0.69	0.33	0.6	0.23	0.64	0.0	0.12	0.68	0.63	0.44	0.66	0.6	0.71	0.53	0.64	0.71	-0.03	0.48	0.67	0.54	-0.22
Total Current Liabilities	0.93	0.86	0.81		0.89	0.88	0.74	0.87	0.18	0.93	0.04	0.02	0.91	0.86	0.85	0.88	0.81	0.88	0.9	0.78	0.87	0.47	0.88	0.78	0.57	-0.34
Total Stockholder Equity	0.98	0.79	0.68	0.89		0.99	0.62	0.98	0.31	0.96	0.34	0.13	0.97	0.94	0.76	0.99	0.92	0.97	0.81	0.91	0.85	0.36	0.8	0.91	0.79	-0.37
Property Plant And Equipment Net	0.96	0.76	0.69	0.88	0.99		0.59	0.96	0.32	0.94	0.35	0.13	0.94	0.92	0.73	0.97	0.91	0.98	0.78	0.9	0.89	0.3	0.78	0.91	0.77	-0.37
Net Debt	0.74	0.93	0.33	0.74	0.62	0.59		0.65	-0.3	0.81	0.12	-0.4	0.72	0.55	0.93	0.66	0.62	0.6	0.91	0.37	0.52	0.74	0.89	0.51	0.4	-0.37
Retained Earnings	0.98	0.83	0.6	0.87	0.98	0.96	0.65		0.33	0.96	0.3	0.17	0.94	0.96	0.81	0.95	0.88	0.91	0.84	0.91	0.79	0.5	0.85	0.85	0.71	-0.31
Cash	0.25	0.06	0.23	0.18	0.31	0.32	-0.3	0.33		0.15	0.18	0.85	0.15	0.39	0.07	0.22	0.17	0.24	0.09	0.61	0.36	-0.08	0.1	0.16	0.08	0.11
Non Current Assets Total	0.99	0.92	0.64	0.93	0.96	0.94	0.81	0.96	0.15		0.28	-0.04	0.97	0.9	0.9	0.96	0.9	0.93	0.93	0.81	0.83	0.54	0.93	0.85	0.7	-0.44
Non Currrent Assets Other	0.29	0.19	0.0	0.04	0.34	0.35	0.12	0.3	0.18	0.28		0.01	0.28	0.2	0.16	0.37	0.27	0.36	0.13	0.28	0.17	-0.23	0.12	0.24	0.51	-0.24
Cash And Short Term Investments	0.07	-0.09	0.12	0.02	0.13	0.13	-0.4	0.17	0.85	-0.04	0.01		-0.07	0.3	-0.09	0.01	-0.05	0.03	-0.07	0.51	0.2	-0.11	-0.09	-0.04	-0.13	0.6
Net Receivables	0.97	0.84	0.68	0.91	0.97	0.94	0.72	0.94	0.15	0.97	0.28	-0.07		0.88	0.8	0.98	0.93	0.96	0.85	0.82	0.79	0.43	0.84	0.9	0.8	-0.49
Common Stock Shares Outstanding	0.93	0.76	0.63	0.86	0.94	0.92	0.55	0.96	0.39	0.9	0.2	0.3	0.88		0.74	0.89	0.79	0.87	0.79	0.92	0.83	0.44	0.81	0.79	0.6	-0.17
Non Current Liabilities Total	0.87	0.99	0.44	0.85	0.76	0.73	0.93	0.81	0.07	0.9	0.16	-0.09	0.8	0.74		0.77	0.7	0.7	0.99	0.62	0.68	0.76	0.98	0.58	0.42	-0.34
Inventory	0.97	0.81	0.66	0.88	0.99	0.97	0.66	0.95	0.22	0.96	0.37	0.01	0.98	0.89	0.77		0.94	0.99	0.81	0.86	0.84	0.35	0.8	0.92	0.82	-0.44
Other Current Assets	0.9	0.75	0.6	0.81	0.92	0.91	0.62	0.88	0.17	0.9	0.27	-0.05	0.93	0.79	0.7	0.94		0.94	0.74	0.8	0.74	0.37	0.71	0.96	0.86	-0.5
Other Stockholder Equity	0.95	0.75	0.71	0.88	0.97	0.98	0.6	0.91	0.24	0.93	0.36	0.03	0.96	0.87	0.7	0.99	0.94		0.76	0.86	0.87	0.24	0.74	0.94	0.83	-0.44
Total Liab	0.91	0.99	0.53	0.9	0.81	0.78	0.91	0.84	0.09	0.93	0.13	-0.07	0.85	0.79	0.99	0.81	0.74	0.76		0.67	0.74	0.72	0.98	0.64	0.46	-0.35
Total Current Assets	0.87	0.65	0.64	0.78	0.91	0.9	0.37	0.91	0.61	0.81	0.28	0.51	0.82	0.92	0.62	0.86	0.8	0.86	0.67		0.8	0.28	0.65	0.78	0.65	-0.09
Short Term Debt	0.85	0.7	0.71	0.87	0.85	0.89	0.52	0.79	0.36	0.83	0.17	0.2	0.79	0.83	0.68	0.84	0.74	0.87	0.74	0.8		0.2	0.75	0.73	0.47	-0.25
Accounts Payable	0.5	0.73	-0.03	0.47	0.36	0.3	0.74	0.5	-0.08	0.54	-0.23	-0.11	0.43	0.44	0.76	0.35	0.37	0.24	0.72	0.28	0.2		0.74	0.21	0.04	-0.14
Intangible Assets	0.9	0.96	0.48	0.88	0.8	0.78	0.89	0.85	0.1	0.93	0.12	-0.09	0.84	0.81	0.98	0.8	0.71	0.74	0.98	0.65	0.75	0.74		0.62	0.41	-0.39
Property Plant And Equipment Gross	0.86	0.64	0.67	0.78	0.91	0.91	0.51	0.85	0.16	0.85	0.24	-0.04	0.9	0.79	0.58	0.92	0.96	0.94	0.64	0.78	0.73	0.21	0.62		0.89	-0.47
Common Stock Total Equity	0.71	0.49	0.54	0.57	0.79	0.77	0.4	0.71	0.08	0.7	0.51	-0.13	0.8	0.6	0.42	0.82	0.86	0.83	0.46	0.65	0.47	0.04	0.41	0.89		-0.51
Short Term Investments	-0.38	-0.35	-0.22	-0.34	-0.37	-0.37	-0.37	-0.31	0.11	-0.44	-0.24	0.6	-0.49	-0.17	-0.34	-0.44	-0.5	-0.44	-0.35	-0.09	-0.25	-0.14	-0.39	-0.47	-0.51

Click cells to compare fundamentals

Bio Techne Account Relationship Matchups

Bio Techne fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.0B	2.3B	2.3B	2.6B	2.7B	2.8B
Short Long Term Debt Total	433.5M	420.6M	326.0M	455.0M	419.5M	440.5M
Other Current Liab	8.3M	62.9M	69.2M	45.3M	63.9M	67.1M
Total Current Liabilities	106.7M	152.3M	176.0M	128.5M	159.4M	167.3M
Total Stockholder Equity	1.4B	1.6B	1.7B	2.0B	2.1B	2.2B
Property Plant And Equipment Net	248.3M	281.7M	288.8M	324.5M	342.4M	359.6M
Net Debt	286.9M	221.5M	153.4M	274.4M	267.7M	281.1M
Retained Earnings	1.1B	1.1B	1.1B	1.3B	1.3B	1.4B
Cash	146.6M	199.1M	172.6M	180.6M	151.8M	89.5M
Non Current Assets Total	1.5B	1.8B	1.7B	2.0B	2.1B	2.2B
Non Currrent Assets Other	13.5M	11.6M	(88.2M)	285.3M	12.1M	16.3M
Cash And Short Term Investments	270.9M	231.6M	247.0M	204.3M	152.9M	137.1M
Net Receivables	122.5M	145.4M	194.5M	218.5M	241.4M	253.5M
Common Stock Shares Outstanding	157.6M	161.9M	164.1M	161.9M	160.8M	169.2M
Liabilities And Stockholders Equity	2.0B	2.3B	2.3B	2.6B	2.7B	2.8B
Non Current Liabilities Total	539.7M	539.4M	417.8M	543.7M	475.6M	499.4M
Inventory	103.2M	116.7M	141.1M	171.6M	179.7M	188.7M
Other Current Assets	24.3M	16.9M	22.9M	27.1M	43.4M	45.6M
Other Stockholder Equity	420.5M	534.4M	653.7M	721.5M	820.3M	861.4M
Total Liab	646.4M	691.7M	593.8M	672.2M	635.0M	666.8M
Total Current Assets	520.9M	510.6M	605.6M	621.5M	617.4M	648.3M
Short Term Debt	22.0M	35.7M	36.4M	22.4M	25.8M	27.1M
Accounts Payable	63.3M	29.4M	33.9M	25.7M	38.0M	39.9M
Intangible Assets	516.5M	616.0M	531.5M	534.6M	507.1M	532.4M
Property Plant And Equipment Gross	248.3M	281.7M	288.8M	324.5M	599.0M	628.9M
Accumulated Other Comprehensive Income	(97.2M)	(57.3M)	(75.2M)	(66.1M)	(78.3M)	(74.4M)
Common Stock Total Equity	385K	390K	392K	1.6M	1.8M	1.9M
Short Term Investments	124.3M	32.5M	74.5M	23.7M	1.1M	1.0M
Common Stock	385K	390K	392K	1.6M	1.6M	1.7M
Other Liab	110.9M	143.0M	116.2M	99.9M	114.9M	97.2M
Other Assets	13.5M	11.6M	46.8M	12.6M	14.5M	8.8M
Long Term Debt	344.2M	328.8M	243.4M	350M	319M	335.0M
Property Plant Equipment	248.3M	281.7M	288.8M	226.2M	260.1M	139.9M
Good Will	728.3M	843.1M	822.1M	872.7M	972.7M	1.0B
Current Deferred Revenue	13.0M	19.0M	23.4M	23.1M	27.9M	29.3M
Net Tangible Assets	136.3M	112.2M	347.4M	652.9M	587.6M	617.0M
Retained Earnings Total Equity	1.1B	1.1B	1.1B	1.3B	1.5B	812.3M
Capital Surpluse	420.5M	534.4M	653.7M	721.5M	829.8M	871.3M
Deferred Long Term Liab	101.1M	93.1M	99.0M	89.0M	102.3M	67.5M

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:

How To Invest In Bio

Details

Is Bio Stock a good investment?

Details

What is Bio Techne's Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.32)

Dividend Share

0.32

Earnings Share

0.95

Revenue Per Share

7.424

Quarterly Revenue Growth

0.045

The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bio Ebit Per Revenue vs Capex To Revenue Analysis

Ebit Per Revenue vs Capex To Revenue

Ebit Per Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Ebit Per Revenue

Capex To Revenue

Bio Techne fundamental ratios Correlations

Bio Techne Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bio Techne fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Net	+ 0.99	Total Stockholder Equity
Inventory	+ 0.99	Total Stockholder Equity
Total Liab	+ 0.99	Non Current Liabilities Total

Short Term Investments	- 0.51	Common Stock Total Equity
Short Term Investments	- 0.5	Other Current Assets
Short Term Investments	- 0.49	Net Receivables
Short Term Investments	- 0.47	Property Plant And Equipment Gross
Short Term Investments	- 0.44	Other Stockholder Equity
Short Term Investments	- 0.44	Inventory